The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | How disease-modifying agents may impact the role of transplantation in patients with MF
Haris Ali, MD, City of Hope, Duarte, CA, shares some insights into how disease-modifying agents may impact the role of transplantation in myelofibrosis (MF). Dr Ali first discusses the importance of clearly defining disease modification, and then goes on to explain how novel agents such as ruxolitinib have improved outcomes in patients undergoing transplantation, and future outlooks. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
